These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 8260707)
1. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Super HJ; McCabe NR; Thirman MJ; Larson RA; Le Beau MM; Pedersen-Bjergaard J; Philip P; Diaz MO; Rowley JD Blood; 1993 Dec; 82(12):3705-11. PubMed ID: 8260707 [TBL] [Abstract][Full Text] [Related]
2. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657 [TBL] [Abstract][Full Text] [Related]
3. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152 [TBL] [Abstract][Full Text] [Related]
4. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Archimbaud E; Charrin C; Magaud JP; Campos L; Thomas X; Fière D; Rimokh R Leukemia; 1998 Jan; 12(1):25-33. PubMed ID: 9436917 [TBL] [Abstract][Full Text] [Related]
5. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. Thirman MJ; Gill HJ; Burnett RC; Mbangkollo D; McCabe NR; Kobayashi H; Ziemin-van der Poel S; Kaneko Y; Morgan R; Sandberg AA N Engl J Med; 1993 Sep; 329(13):909-14. PubMed ID: 8361504 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the MLL breakpoint cluster region (BCR). Echlin-Bell DR; Smith LL; Li L; Strissel PL; Strick R; Gupta V; Banerjee J; Larson R; Relling MV; Raimondi SC; Hayashi Y; Taki T; Zeleznik-Le N; Rowley JD Hum Genet; 2003 Jul; 113(1):80-91. PubMed ID: 12665971 [TBL] [Abstract][Full Text] [Related]
7. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019 [TBL] [Abstract][Full Text] [Related]
8. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? Dissing M; Le Beau MM; Pedersen-Bjergaard J J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906 [TBL] [Abstract][Full Text] [Related]
9. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977 [TBL] [Abstract][Full Text] [Related]
10. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Broeker PL; Super HG; Thirman MJ; Pomykala H; Yonebayashi Y; Tanabe S; Zeleznik-Le N; Rowley JD Blood; 1996 Mar; 87(5):1912-22. PubMed ID: 8634439 [TBL] [Abstract][Full Text] [Related]
11. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462 [TBL] [Abstract][Full Text] [Related]
12. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Strissel PL; Strick R; Rowley JD; Zeleznik-Le NJ Blood; 1998 Nov; 92(10):3793-803. PubMed ID: 9808573 [TBL] [Abstract][Full Text] [Related]
13. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia. Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569 [TBL] [Abstract][Full Text] [Related]
14. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs]. Dassonneville L; Bailly C Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316 [TBL] [Abstract][Full Text] [Related]
15. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Hunger SP; Tkachuk DC; Amylon MD; Link MP; Carroll AJ; Welborn JL; Willman CL; Cleary ML Blood; 1993 Jun; 81(12):3197-203. PubMed ID: 8389614 [TBL] [Abstract][Full Text] [Related]
16. Secondary leukemias induced by topoisomerase-targeted drugs. Felix CA Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598 [TBL] [Abstract][Full Text] [Related]
17. Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia. Sait SN; Claydon MA; Conroy JM; Nowak NJ; Barcos M; Baer MR Cancer Genet Cytogenet; 2007 Sep; 177(2):143-6. PubMed ID: 17854671 [TBL] [Abstract][Full Text] [Related]
18. Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not Zuo W; Wang SA; DiNardo C; Yabe M; Li S; Medeiros LJ; Tang G J Clin Pathol; 2017 Mar; 70(3):244-249. PubMed ID: 27496968 [TBL] [Abstract][Full Text] [Related]
19. Rearrangements involving chromosome band 11Q23 in acute leukaemia. Rowley JD Semin Cancer Biol; 1993 Dec; 4(6):377-85. PubMed ID: 8142623 [TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J; Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]